Latest Immunotherapy Treatments
Researchers from China tried to determine whether immunotherapy or chemotherapy is better as a second line treatment option for relapsed pleural mesothelioma. There is no current standard therapy for people whose mesothelioma comes back, which makes it hard for doctors to make treatment decisions for patients. Mesothelioma is very aggressive, and no treatments are available…
A YAP/TEAD inhibitor is showing promising results for people with mesothelioma and other cancers. The inhibitor, known as VT3989, was well tolerated and had good anti-tumor effects in cancer patients with mesothelioma and NF2 mutations. Results were recently published from the first human study. Seven of 69 patients had radiological partial responses, which includes tumor…
Keytruda is showing promising results for the treatment of pleural mesothelioma. Researchers found that the combination of Keytruda (pembrolizumab) and chemotherapy lead to a better survival in patients versus chemotherapy alone. Mesothelioma is a hard-to-treat cancer with no cure. It can be found in the linings of the lungs, abdomen, heart, and testicles. The aggressive…
A vaccine for lung cancer could possibly lead to a vaccine for mesothelioma. The lung cancer immunotherapy drug CIMAvax-EFG is making great progress, and because of this progress, researchers are utilizing the treatment in new ways. The researchers are trying to see how the vaccine can be used to prevent cancer instead of just treating…
A new study from Rice University in Houston is showing promising results for mesothelioma. It utilizes the immune system to fight cancer cells. The protein that is being studied is interleukin 2 (IL2), which is a protein that regulates white blood cells through the use of cytokines, a cell signal that affects other cells. When…
There might be more options for treating mesothelioma. A study looked at the combination of Opdivo and Yervoy after surgery. The study was performed at the Hyogo College of Medicine in Japan. Opdivo and Yervoy, which were recently approved for the treatment of mesothelioma, improved survival when administered after surgery. The six-month survival was 87…
Immunotherapy before aggressive surgery shows great promise for pleural mesothelioma. The combination has shown that it can improve survival for a group of patients with pleural mesothelioma in a phase II study at Baylor College of Medicine. The treatment uses two immune checkpoint inhibitors, durvalumab and tremelimumab. The two drugs have shown that they can…
A study looking at T-cell therapy for mesothelioma is going to phase II of the clinical trial process. Researchers are trying to find out how effective the treatment is when combined with an approved immunotherapy combination. Researchers are looking at the relationship between gavocabtagene autoleucel (gavo-cel) with the combination of Opdivo and Yervoy. The combination…
Pleural mesothelioma sufferers could improve their survival by as much as 30 percent when treated with the latest cancer enzyme and chemotherapy. In a recent study known as ATOMIC Meso, ADI-PEG 20 showed effectiveness when used for sarcomatoid and biphasic mesothelioma, the two most resistive to treatment. The enzyme is able to limit an amino…
Early next year, a new clinical trial will be conducted to test an immunotherapy treatment that has a new and unique delivery system. The study will be conducted at the University of Pennsylvania. The Food and Drug Administration gave orphan drug status to SynKIR-110, a CAR T-cell therapy utilized for solid tumors (including mesothelioma) that…
